TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Salesforce Falls In Spite of Earnings Beat, Strong Full-Year Guidance
JIM CRAMER

Smartsheet, Prudential, Salesforce.com: 'Mad Money' Lightning Round

  • By Scott Rutt
  • Jul 10, 2018 6:34 AM EDT
PRESS RELEASES

Editas Medicine Announces Offering Of Common Stock

  • By GlobeNewswire
  • Jan 19, 2021 4:01 PM EST
PRESS RELEASES

Editas Medicine Reports On Recent Progress And Outlook At J.P. Morgan Healthcare Conference

  • By GlobeNewswire
  • Jan 11, 2021 6:05 AM EST
PRESS RELEASES

Editas Medicine Announces The FDA Has Cleared Initiation Of The EDIT-301 Clinical Trial

  • By GlobeNewswire
  • Jan 11, 2021 6:02 AM EST
PRESS RELEASES

Editas Medicine Announces Transition Of Chief Scientific Officer

  • By GlobeNewswire
  • Jan 11, 2021 6:00 AM EST
PRESS RELEASES

Editas Medicine To Present At The 39th Annual J.P. Morgan Healthcare Conference

  • By GlobeNewswire
  • Jan 4, 2021 4:05 PM EST
PRESS RELEASES

Editas Medicine Names Meeta Chatterjee, Ph.D., To Board Of Directors

  • By GlobeNewswire
  • Dec 17, 2020 4:05 PM EST
PRESS RELEASES

Editas Medicine Announces Submission Of IND Application For EDIT-301 With The FDA

  • By GlobeNewswire
  • Dec 9, 2020 4:01 PM EST
PRESS RELEASES

Editas Medicine Announces Preclinical Data And Large-Scale Manufacturing Process For EDIT-301, In Development For The Treatment Of Sickle Cell Disease And Beta-Thalassemia

  • By GlobeNewswire
  • Dec 5, 2020 10:00 AM EST
PRESS RELEASES

Editas Medicine Reports Inducement Grants To New Chief Medical Officer

  • By GlobeNewswire
  • Nov 10, 2020 4:01 PM EST
PRESS RELEASES

Editas Medicine To Present At Barclays Gene Editing & Gene Therapy Summit

  • By GlobeNewswire
  • Nov 9, 2020 4:05 PM EST
PRESS RELEASES

Editas Medicine Appoints Lisa A. Michaels, M.D., As Chief Medical Officer

  • By GlobeNewswire
  • Nov 9, 2020 9:00 AM EST
PRESS RELEASES

Editas Medicine To Participate In Upcoming Investor Conference

  • By GlobeNewswire
  • Oct 1, 2020 8:00 AM EDT
PRESS RELEASES

Editas Medicine Announces U.S. Patent And Trademark Office Grants The Broad Institute Priority Benefit In CRISPR Interference

  • By GlobeNewswire
  • Sep 11, 2020 7:00 AM EDT
PRESS RELEASES

Editas Medicine To Participate In Upcoming Investor Conferences

  • By GlobeNewswire
  • Sep 4, 2020 8:00 AM EDT
PRESS RELEASES

Editas Medicine Receives Rare Pediatric Disease Designation For EDIT-301 For The Treatment Of Sickle Cell Disease

  • By GlobeNewswire
  • Aug 24, 2020 8:30 AM EDT
PRESS RELEASES

Editas Medicine Regains Full Global Rights To Ocular Medicines

  • By GlobeNewswire
  • Aug 6, 2020 4:01 PM EDT
PRESS RELEASES

Catalent Enters Into Strategic Partnership With Editas Medicine To Support Gene Editing Medicine Pipeline

  • By GlobeNewswire
  • Jul 29, 2020 8:00 AM EDT
PRESS RELEASES

Editas Medicine To Host Conference Call Discussing Second Quarter 2020 Results And Corporate Update

  • By GlobeNewswire
  • Jul 23, 2020 4:01 PM EDT
PRESS RELEASES

Editas Medicine And Azzur Group Announce A Multi-year Agreement For EDIT-301 And EDIT-201 Manufacturing

  • By GlobeNewswire
  • Jul 7, 2020 9:00 AM EDT
PRESS RELEASES

Editas Medicine And Azzur Group Announce A Multi-year Agreement For EDIT-301 And EDIT-201 Manufacturing

  • By PR Newswire
  • Jul 7, 2020 9:00 AM EDT
PRESS RELEASES

Editas Medicine Announces Closing Of Offering Of Common Stock And Full Exercise By Underwriter Of Option To Purchase Additional Shares

  • By GlobeNewswire
  • Jun 26, 2020 4:05 PM EDT
PRESS RELEASES

Editas Medicine Announces Pricing Of Offering Of Common Stock

  • By GlobeNewswire
  • Jun 23, 2020 9:48 PM EDT
PRESS RELEASES

Editas Medicine Announces Offering Of Common Stock

  • By GlobeNewswire
  • Jun 23, 2020 4:21 PM EDT
PRESS RELEASES

Editas Medicine Presents Pre-Clinical Data From A Study Of EDIT-301 With Sickle Patient Cells For The Potential Treatment Of Sickle Cell Disease

  • By GlobeNewswire
  • Jun 12, 2020 6:00 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.